Ascendis Pharma A/s
Clinical trials sponsored by Ascendis Pharma A/s, explained in plain language.
Develops prodrug therapies for endocrine and metabolic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a weekly shot replace daily growth hormone for kids?
Disease control CompletedThis study tests a new long-acting growth hormone called ACP-001, given as a once-weekly injection, in children with growth hormone deficiency. It compares the safety and effectiveness of this weekly shot to the standard daily growth hormone injections over six months. The goal i…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Weekly shot could replace daily hormone injections for adults
Disease control CompletedThis study tests a new once-weekly growth hormone injection (ACP-001) in adults with growth hormone deficiency. It compares three different doses of the weekly shot against a standard daily growth hormone product over four weeks. The goal is to see if the weekly injection is safe…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Weekly shot could replace daily needles for kids with growth hormone deficiency
Disease control CompletedThis study tests a long-acting growth hormone called TransCon hGH, given as a once-weekly injection, in children with growth hormone deficiency who have already completed a prior TransCon trial. The goal is to see if the weekly shot remains safe and effective over the long term. …
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Weekly shot may boost growth in kids with dwarfism
Disease control CompletedThis study tests a weekly injection called TransCon CNP in children aged 2 to 10 with achondroplasia, the most common form of dwarfism. The goal is to see if it can safely improve growth over one year. Half the children receive the drug and half receive a placebo, and all childre…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New daily shot could ease rare hormone disorder
Disease control CompletedThis phase 2 trial tested a daily injection called TransCon PTH in 59 adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. Participants were randomly assigned to receive either the drug or a placebo for four weeks, followed by an ope…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC